EPSTEIN-BARR VIRUS INDUCED GENOMIC INSTABILITY
爱泼斯坦-巴尔病毒引起的基因组不稳定
基本信息
- 批准号:2330935
- 负责人:
- 金额:$ 23.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-04-05 至 2000-01-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS AIDS related neoplasm /cancer DNA replication Epstein Barr virus Herpesviridae T cell receptor chemical stability enzyme activity gene expression gene induction /repression human subject immunoglobulin genes lymphoma molecular cloning neoplasm /cancer genetics neoplasm /cancer immunology nonHodgkin's lymphoma nucleic acid sequence recombinase southern blotting transfection viral carcinogenesis virus DNA virus integration virus related neoplasm /cancer
项目摘要
The long term goal of this research is to understand the molecular
mechanisms by which the Epstein-Barr virus (EBV) causes cancer. EBV is
associated with nasopharyngeal carcinoma, endemic Burkitt's lymphoma
(BL), and Hodgkin's lymphoma. We contend that AIDS-related lymphomas
offer novel insights into EBV oncogenesis because immunosuppression
unmasks properties intrinsic to the virus that may be central to its
pathobiology. Identification in AIDS patients of 11 a defective EBV
genome that disrupts viral latency, 2/ a unique EBV replicative lesion
(oral hairy leukoplakia), and 31 lytic antigens in AIDS-related lymphomas
all confirm the validity of this notion. Whereas 6 nuclear antigens and
3 membrane proteins expressed in latent infection of lymphoblastoid cells
are recognized as contributing to EBV-induced lymphoproliferation, a role
for replicative cycle proteins has not been appreciated. We now
hypothesize that, as part of the viral replicative process, this
lymphotropic herpesvirus activates site-specific recombinases involved
in diversification of immunoglobulin and T cell receptor genes. Biologic
consequences include generation of defective EBV genomes with novel
pathogenic potential, virus integration into the host genome, and the
introduction of genomic instability. Specific aims to test this
hypothesis are: II determine the EBV gene product that induces expression
of recombinase activating genes l and 2 (RAG1&2); 2) evaluate the effect
of V(D)J recombinase on EBV genomic organization; 3) elucidate pathogenic
consequences of EBV-associated RAG expression.
EBV induction of RAG expression by genes required for viral DNA
replication (EBNA1 and BZLF1) will be examined in transfection assays at
the RNA, protein and functional levels (aim 1). EBV and cellular DNA
breakpoints from cloned integration sites in BL cells will be sequenced
to determine presence of V(D)J recognition signal sequences (RSS). EBV
intermolecular and intragenic rearrangements will be sequenced for
hallmarks of V(D)J recombinase joining: presence of heptamer/nanomer RSS,
junctional loss and addition of nucleotides (aim 2). Finally, using AIDS-
related lymphomas, clinical correlations will be made by parallel
analyses for integration of unit length and defective EBV DNA (aim 3).
Aberrant V(D)J recombinase expression during viral DNA replication would
provide the first indication that EBV reactivation in chronic virus
carriers has a direct role in the oncogenic process and would provide a
rationale for antiviral interventions during the severe immunosuppression
of AIDS.
这项研究的长期目标是了解
EB病毒(EBV)引起癌症的机制。EBV是
与鼻咽癌、地方性伯基特淋巴瘤相关
(BL)和霍奇金淋巴瘤我们认为艾滋病相关的淋巴瘤
为EBV肿瘤发生提供了新的见解,因为免疫抑制
揭示了病毒固有的特性,这些特性可能是其
病理生物学艾滋病患者EB病毒11a缺陷型的鉴定
破坏病毒潜伏期的基因组,2/一种独特的EBV复制性损伤
(oral毛状白斑)和艾滋病相关淋巴瘤中的31种裂解抗原
都证实了这一观点的正确性。而6个核抗原和
3种膜蛋白在淋巴母细胞潜伏感染中的表达
被认为有助于EBV诱导的淋巴细胞增殖,
对于复制周期蛋白的作用还没有被认识到。我们现在
假设,作为病毒复制过程的一部分,
嗜淋巴细胞疱疹病毒激活位点特异性重组酶
免疫球蛋白和T细胞受体基因的多样化。生物
其后果包括产生具有新的缺陷的EBV基因组,
致病潜力,病毒整合到宿主基因组中,以及
引入基因组不稳定性。具体目标是测试这一点
假设是:II确定诱导表达的EBV基因产物
重组酶激活基因1和2(RAG1和2)的表达; 2)评估重组酶激活基因1和2(RAG1和2)的作用
V(D)J重组酶对EBV基因组结构的影响; 3)阐明EBV的致病性
EBV相关RAG表达的后果。
EBV通过病毒DNA所需基因诱导RAG表达
复制(EBNA1和BZLF1)将在转染试验中检查,
RNA、蛋白质和功能水平(目标1)。EBV和细胞DNA
将对BL细胞中克隆的整合位点的断点进行测序
以确定V(D)J识别信号序列(RSS)的存在。EBV
将对分子间和基因内重排进行测序,
V(D)J重组酶连接的标志:存在七聚体/纳米聚体RSS,
核苷酸的连接丢失和添加(目的2)。最后,利用艾滋病-
相关淋巴瘤,临床相关性将通过平行
分析单位长度和缺陷EBV DNA的整合(目的3)。
病毒DNA复制过程中V(D)J重组酶的异常表达
提供了第一个迹象表明,EBV在慢性病毒
携带者在致癌过程中有直接作用,
严重免疫抑制期间抗病毒干预的基本原理
艾滋病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN W SIXBEY其他文献
JOHN W SIXBEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN W SIXBEY', 18)}}的其他基金
Epstein-Barr Virus-Enhanced Tumor Progression
Epstein-Barr 病毒增强的肿瘤进展
- 批准号:
7414860 - 财政年份:2006
- 资助金额:
$ 23.32万 - 项目类别:
Epstein-Barr Virus-Enhanced Tumor Progression
Epstein-Barr 病毒增强的肿瘤进展
- 批准号:
7247107 - 财政年份:2006
- 资助金额:
$ 23.32万 - 项目类别:
Epstein-Barr Virus-Enhanced Tumor Progression
Epstein-Barr 病毒增强的肿瘤进展
- 批准号:
7146318 - 财政年份:2006
- 资助金额:
$ 23.32万 - 项目类别:
DETERMINANTS OF EPSTEIN BARR VIRUS MUCOSAL PATHOGENESIS
爱泼斯坦巴尔病毒粘膜发病的决定因素
- 批准号:
2458673 - 财政年份:1996
- 资助金额:
$ 23.32万 - 项目类别:
DETERMINANTS OF EPSTEIN BARR VIRUS MUCOSAL PATHOGENESIS
爱泼斯坦巴尔病毒粘膜发病的决定因素
- 批准号:
6176107 - 财政年份:1996
- 资助金额:
$ 23.32万 - 项目类别:
DETERMINANTS OF EPSTEIN BARR VIRUS MUCOSAL PATHOGENESIS
爱泼斯坦巴尔病毒粘膜发病的决定因素
- 批准号:
2897144 - 财政年份:1996
- 资助金额:
$ 23.32万 - 项目类别:
DETERMINANTS OF EPSTEIN BARR VIRUS MUCOSAL PATHOGENESIS
爱泼斯坦巴尔病毒粘膜发病的决定因素
- 批准号:
2749379 - 财政年份:1996
- 资助金额:
$ 23.32万 - 项目类别:
DETERMINANTS OF EPSTEIN BARR VIRUS MUCOSAL PATHOGENESIS
爱泼斯坦巴尔病毒粘膜发病的决定因素
- 批准号:
2015466 - 财政年份:1996
- 资助金额:
$ 23.32万 - 项目类别:
Epstein Barr Virus Induced Genomic Instability
EB 病毒引起的基因组不稳定
- 批准号:
6881605 - 财政年份:1995
- 资助金额:
$ 23.32万 - 项目类别:
EPSTEIN-BARR VIRUS INDUCED GENOMIC INSTABILITY
爱泼斯坦-巴尔病毒引起的基因组不稳定
- 批准号:
2654182 - 财政年份:1995
- 资助金额:
$ 23.32万 - 项目类别: